We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Method Simplifies Preparation of Tumor Genomic DNA Libraries

By LabMedica International staff writers
Posted on 28 Oct 2019
Print article
Image: A diagram of construction of a genomic library (Photo courtesy of Wikimedia Commons).
Image: A diagram of construction of a genomic library (Photo courtesy of Wikimedia Commons).
A method has been described that simplifies preparation of tumor genomic DNA libraries by employing restriction enzymes and in vitro transcription to barcode and amplify genomic DNA prior to library construction.

In general, a genomic library is the collection of the total genomic DNA from a single organism. The DNA is stored in a population of identical vectors, each containing a different insert of DNA. In order to construct a genomic library, the organism's DNA is extracted from cells and then digested with a restriction enzyme to cut the DNA into fragments of a specific size. The fragments are then inserted into the vector using DNA ligase.

Copy number alterations or variations are common features of cancer cells. Within the same tumor, cells belonging to different anatomical areas of the tumor may carry different variations. Tumors with many variations are typically very aggressive and tend to be resistant to treatment.

Current strategies for massively parallel sequencing of tumor genomic DNA mainly rely on library indexing in the final steps of library preparation. This procedure is costly and time-consuming, since a library must be generated separately for each sample. Furthermore, whole-genome amplification requires intact DNA and thus is problematic in fixed tissue samples, in particular formalin-fixed, paraffin-embedded (FFPE) specimens, which still represent a cornerstone in pathology.

To overcome these limitations, investigators at the Karolinska Institutet (Solna, Sweden) developed a method, which they named CUTseq, that combined restriction endonucleases with in vitro transcription (IVT) to construct highly multiplexed DNA libraries for reduced representation genome sequencing of multiple samples in parallel.

The investigators showed that CUTseq could be used to barcode gDNA extracted from both non-fixed and fixed samples, including old archival FFPE tissue sections. They benchmarked CUTseq by comparing it with a widely used method of DNA library preparation and demonstrated that CUTseq could be used for reduced representation genome and exome sequencing, enabling reproducible DNA copy number profiling and single-nucleotide variant (SNV) calling in both cell and low-input FFPE tissue samples.

The investigators demonstrated an application of CUTseq for assessing genetic differences within tumors by profiling DNA copy number levels in multiple small regions of individual FFPE tumor sections. Finally, they described a workflow for rapid and cost-effective preparation of highly multiplexed CUTseq libraries, which could be applied in the context of high-throughput genetic screens and for cell line authentication.

"I expect that CUTseq will find many useful applications in cancer diagnostics," said senior author Dr. Nicola Crosetto, senior researcher in medical biochemistry and biophysics at the Karolinska Institutet. "Multi-region tumor sequencing is going to be increasingly used in the diagnostic setting, in order to identify patients with highly heterogeneous tumors that need to be treated more aggressively. I believe that our method can play a leading role here."

The study was published in the October 18, 2019, online edition of the journal Nature Communications.

Related Links:
Karolinska Institutet

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Coagulation Analyzer
CS-2400

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.